Claims
- 1. A method of treating secondary lymphedema, comprising:
administering to a patient with secondary lymphedema a therapeutically effective amount of DNA encoding vascular endothelial growth factor-D (VEGF-D).
- 2. A method of claim 1, wherein said patient is human
- 3. A method of claim 2, wherein said DNA is circular.
- 4. A method of claim 3, wherein said DNA is a plasmid.
- 5. A method of treating secondary lymphedema, comprising:
administering to a patient with secondary lymphedema a therapeutically effective amount of DNA encoding VEGF-D, wherein said secondary lymphedema is caused by at least one of inflammatory obstruction of lymphatic vessels, neoplastic obstruction of lymphatic vessels, accumulation of ascites fluid due to peritoneal carcinomatosis, and edema of at least one limb.
- 6. A method of claim 5, wherein said edema follows at least one of surgery and radiotherapy for a neoplastic disease.
- 7. A method of claim 6, wherein said neoplastic disease is breast cancer.
- 8. A method of claim 6, wherein said neoplastic disease is at least one tumor type.
- 9. A method of inhibiting secondary lymphedema, comprising:
administering to a patient at risk for secondary lymphedema a therapeutically inhibitory amount of DNA encoding VEGF-D.
- 10. A method for expressing VEGF-D in a target cell, comprising
selecting a plasmid capable of expressing DNA encoding VEGF-D, wherein said plasmid has at least one insertion site for insertion of said DNA encoding VEGF-D operably linked to a promoter capable of expression in said target cell; inserting said DNA encoding VEGF-D into said insertion site, and introducing said plasmid into said target cell wherein said DNA encoding VEGF-D is expressed at detectable levels.
- 11. A method of treating secondary lymphedema, comprising:
administering to a patient with secondary lymphedema a therapeutically effective amount of at least one plasmid encoding VEGF-DΔNΔC.
- 12. A method of treating secondary lymphedema, comprising:
administering to a patient with secondary lymphedema a therapeutically effective amount of vascular endothelial growth factor-D (VEGF-D) protein.
- 13. A method of claim 12, wherein said patient is human
- 14. A method of treating secondary lymphedema, comprising:
administering to a patient with secondary lymphedema a therapeutically effective amount of VEGF-D protein, wherein said secondary lymphedema is caused by at least one of inflammatory obstruction of lymphatic vessels, neoplastic obstruction of lymphatic vessels, accumulation of ascites fluid due to peritoneal carcinomatosis, and edema of at least one limb.
- 15. A method of claim 14, wherein said edema follows surgery or radiotherapy for a neoplastic disease.
- 16. A method of claim 15 wherein said neoplastic disease is breast cancer.
- 17. A method of claim 15, wherein said neoplastic disease is at least one tumor type.
- 18. A method of inhibiting secondary lymphedema, comprising:
administering to a patient at risk for secondary lymphedema a therapeutically preventative amount of VEGF-D protein.
- 19. A method of claim 1, wherein said DNA encoding VEGF-D is administered to said patient by at least one DNA virus.
- 20. A method of claim 1, wherein said DNA encoding VEGF-D is administered to said patient by at least one of an adenovirus, a herpesvirus, a parvovirus, and an avipox virus.
- 21. A method of claim 1, wherein said DNA encoding VEGF-D is administered to said patient by at least one liposome.
- 22. A method of claim 1, wherein said lymphedema is idiopathic.
- 23. A method of claim 12, wherein said lymphedema is idiopathic.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims priority of U.S. Provisional Application No. 60/377,253 filed May 3, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60377253 |
May 2002 |
US |